Aviceda Therapeutics is a private clinical-stage biotech company focused on the next generation of glyco-immune therapeutics that leverage its proprietary High-Affinity Ligands of Siglecs (HALOS ™) technology platform to address immune-mediated inflammatory disorders inflammatory diseases of the innate immune system including geographic atrophy (GA) from age-related macular degeneration (AMD), Immunology, Fibrosis, Cancer and Neurologic diseases,...
Aviceda Therapeutics is a private clinical-stage biotech company focused on the next generation of glyco-immune therapeutics that leverage its proprietary High-Affinity Ligands of Siglecs (HALOS ™) technology platform to address immune-mediated inflammatory disorders inflammatory diseases of the innate immune system including geographic atrophy (GA) from age-related macular degeneration (AMD), Immunology, Fibrosis, Cancer and Neurologic diseases,...
Aviceda Therapeutics is a private clinical-stage biotech company focused on the next generation of glyco-immune therapeutics that leverage its proprietary High-Affinity Ligands of Siglecs (HALOS ™) technology platform to address immune-mediated inflammatory disorders inflammatory diseases of the innate immune system including geographic atrophy (GA) from age-related macular degeneration (AMD), Immunology, Fibrosis, Cancer and Neurologic diseases,...
